In patients with B-cell malignancies, treatment with the first-generation Bruton tyrosine kinase (BTK) inhibitor ibrutinib can be limited by toxicities resulting from off-target binding. Zanubrutinib, a next-generation BTK inhibitor, was designed to maximize BTK occupancy and minimize off-target effects.
ESMO Open published a clinical update in Oncology on 10 Mar 2026.
The item focuses on Pooled safety analysis of zanubrutinib monotherapy in Asian patients with B-cell malignancies.
Review the original article for the full source wording and details.